5-chlorotryptamine is a tryptamine derivative that has been studied for its potential pharmacological and therapeutic effects. It is a serotonin receptor agonist with a high affinity for the 5-HT2A receptor, which is involved in a variety of physiological processes including mood, cognition, and perception. 5-chlorotryptamine has also been shown to have antipsychotic and anxiolytic effects in animal models. It is synthesized through various methods, including the condensation of indole with 5-chlorobenzaldehyde. Studies on 5-chlorotryptamine explore its role in neurotransmission, its potential as a therapeutic agent for conditions like anxiety and schizophrenia, and its interactions with other neurochemicals. The compound's ability to modulate serotonin signaling pathways makes it an interesting target for research into the development of novel drugs.'
| ID Source | ID |
|---|---|
| PubMed CID | 77379 |
| CHEMBL ID | 1288716 |
| SCHEMBL ID | 626030 |
| MeSH ID | M0521808 |
| Synonym |
|---|
| CBMICRO_013645 |
| 5-chlorotryptamine |
| BB 0242423 |
| einecs 223-184-6 |
| 5-chloro-1h-indole-3-ethylamine |
| EU-0011875 |
| OPREA1_792077 |
| 2-(5-chloro-1h-indol-3-yl)ethanamine |
| STK386806 |
| AKOS000266602 |
| HMS1613J03 |
| 3764-94-1 |
| bdbm50331286 |
| 5-cl-t |
| CHEMBL1288716 , |
| 2-(5-chloro-1h-indol-3-yl)ethan-1-amine |
| BBL010651 |
| CCG-20517 |
| 5-chloro-1h-indole-3-ethanamine |
| smsf0003286 |
| CB05124 |
| FT-0635010 |
| AB03687 |
| 2-(5-chloro-1h-indol-3-yl)-ethylamine |
| SCHEMBL626030 |
| 2-(5-chloro-1h-indol-3-yl) ethanamine |
| 1h-indole-3-ethanamine, 5-chloro- |
| 2-(5-chloro-1h-indol-3-yl)ethylamine # |
| DTXSID50191073 |
| mfcd00130168 |
| 2-(5-chloranyl-1~{h}-indol-3-yl)ethanamine |
| 6so , |
| indole, 3-(2-aminoethyl)-5-chloro- |
| AS-44802 |
| 2-(5-chloro-1h-indol-3-yl)ethylamine |
| AB6844 |
| EN300-144160 |
| PD094244 |
| SY027680 |
| 9V4S232P62 |
| 2-(5-chloro-1h-indol-3-yl)-1-ethanamine |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Transient receptor potential cation channel subfamily M member 8 | Homo sapiens (human) | IC50 (µMol) | 26.8500 | 0.0200 | 1.2755 | 3.9000 | AID538746; AID538747 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | EC50 (µMol) | 0.0041 | 0.0000 | 0.2276 | 3.4750 | AID1162842 |
| Transporter | Rattus norvegicus (Norway rat) | EC50 (µMol) | 0.0041 | 0.0005 | 0.0478 | 0.3300 | AID1162842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID538747 | Antagonist activity at human TRPM8 receptor expressed in human T-REx-293 cells assessed as inhibition of icilin-induced 45calcium influx treated 5 mins before icilin challenge measured after 5 mins | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | 5-benzyloxytryptamine as an antagonist of TRPM8. |
| AID538746 | Antagonist activity at human TRPM8 receptor expressed in human T-REx-293 cells assessed as inhibition of menthol-induced 45calcium influx treated 5 mins before menthol challenge measured after 5 mins | 2010 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23 | 5-benzyloxytryptamine as an antagonist of TRPM8. |
| AID1162841 | Induction of NET-mediated norepinephrine release in rat brain synaptosomes by [3H]NE release assay | 2014 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19 | Alpha-ethyltryptamines as dual dopamine-serotonin releasers. |
| AID1162843 | Agonist activity at 5HT2A receptor (unknown origin) by cell based calcium mobilization assay relative to control | 2014 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19 | Alpha-ethyltryptamines as dual dopamine-serotonin releasers. |
| AID1162842 | Agonist activity at 5HT2A receptor (unknown origin) by cell based calcium mobilization assay | 2014 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19 | Alpha-ethyltryptamines as dual dopamine-serotonin releasers. |
| AID1162840 | Induction of 5-HTT-mediated 5-HT release in rat brain synaptosomes by [3H]5-HT release assay | 2014 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19 | Alpha-ethyltryptamines as dual dopamine-serotonin releasers. |
| AID1162839 | Induction of DAT-mediated dopamine release in rat brain synaptosomes by [3H]DA release assay | 2014 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19 | Alpha-ethyltryptamines as dual dopamine-serotonin releasers. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.63) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||